Open AccessSystemic therapy in addition to cytoreduction and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: recent insights from clinical studies and translational research
Author(s) -
Checca Bakkers,
Geert A. Simkens,
Ignace H. J. T. de Hingh
Publication year - 2021
Publication title -
journal of gastrointestinal oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.084
H-Index - 39
eISSN - 2219-679X
pISSN - 2078-6891
DOI - 10.21037/jgo-20-133
Subject(s) - medicine , hyperthermic intraperitoneal chemotherapy , systemic therapy , cytoreductive surgery , translational research , intraperitoneal chemotherapy , chemotherapy , colorectal cancer , oncology , adjuvant , peritoneal carcinomatosis , clinical trial , adjuvant therapy , surgery , cancer , pathology , ovarian cancer , breast cancer
There is a lack of randomized or high-quality intention-to-treat cohort studies addressing the role of systemic therapy in addition to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) as part of the treatment of colorectal peritoneal metastases (PM). Therefore, the choice whether or not to treat patients with systemic therapy is currently mainly based on expert opinion. As a result, treatment with neoadjuvant and/or adjuvant systemic therapy is implemented in various ways around the world. The aim of this review was to provide an overview of recent insights with regard to the systemic treatment of PM of colorectal origin obtained from clinical studies and translational research.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom